This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Fluoroquinolones in conjunctivitis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Both ciprofloxacin and ofloxacin are licensed for external ocular infections. Both have broad spectrum bactericidal activity, particularly against Gram-negatives, but the former is more efficacious against Pseudomonas aeruginosa and the latter against Chlamydia trachomatis.

Randomised controlled trials have shown both drugs to be as effective clinically as traditional topical preparations such as chloramphenicol(1,2).

However, both drugs have a number of adverse effects e.g. eye irritation, and are expensive in comparison to chloramphenicol.

Their use should be reserved for superficial infections with known resistance to traditional first-line drugs and sensitivity to the fluoroquinolone.

Reference:

  • (1) Bron, A.J., Leber, G., Rizk, S.N.M. et al. (1991). Ofloxacin compared with chloramphenicol in the management of external ocular infection. Br. J. Ophthalmol, 75, 675-679.
  • (2) Power, W.J., Collum, L.M.T. et al. (1993). Evaluation of efficacy and safety of ciprofloxacin ophthalmic solution versus chloramphenicol. Eur. J. Ophthalmol, 3, 77-82.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.